Lectenz® Bio’s financial strategy targets a combination of grants (private, state, and federal), and strategic academic and industrial partnerships. The company has previously received non-dilutive seed funding grants from the Georgia Research Alliance and has subsequently secured multi-million dollars in non-dilutive funding from the NIH for product development. The company continues to target additional non-dilutive funding to support product development activities and has a robust pipeline of grant applications to support the development of additional Lectenz® and GlycoSenseTM product lines.
The company has had no outside investment to date. Interim funds are sought in 2017 in the form of a convertible note to finance for product launch, customer acquisition, talent recruitment, and operational expansion. The company is also prioritizing securing strategic product development partnerships and establishing channel partnerships for product sales, marketing, and distribution.
The company anticipates securing private equity investment in 2018 to accelerate its growth plans to develop into a high growth venture by scaling operations, expanding glycan analysis products offerings in Biopharma bioprocessing and R&D markets, talent recruitment, and increasing customer acquisition. The company mitigates high operational costs by balancing development between internal resources at local incubators, universities, and external vendors. Please contact us to learn more about our team, our strategy, and the market opportunity.
A diverse portfolio of products will ensure multiple revenue streams including the sale (direct or via distributors) of Lectenz® based kits and services. The successful development of the Lectenz® reagents has allowed the company to develop a diverse portfolio of products and services including:
- Lectenz® and GlycoSenseTM kits for glycomics analysis will be made available to customers through value added resellers and distributors.
- The Sia-3S1 Lectenz® kit is for the enrichment of 2,3-linked sialo-glycans.
- The Sia-PS1 Lectenz® kit is for the enrichment of all sialo-glycans independent of linkage.
- The NG2 Lectenz® kit is for the enrichment of N-linked glycopeptides for downstream analysis by MS.
- Additional Lectenz® reagents will be engineered to further enrich the sample in specific glycan sub-structures. These additional Lectenz® will be made available in multiple product embodiments. For example, as the product line expands and matures, the kits may be offered in several formats, including as affinity columns for use with existing FPLC/HPLC/MS technologies, or in microarray format, or in microsphere format for flow-based analyses.
- The company will be expanding is product portfolio beyond Lectenz® that recognize sialic acid and N-glycans. Lectenz® specific for cancer glycans biomarkers, and for characterizing specific glycans such as heparin or O-GlcNAc are already under development.
- Service for custom engineered Lectenz® and GlycoSenseTM kits will be available for highly customized applications per customer needs.
- Joint ventures through strategic partnerships that employ the company’s Lectenz® engineering platform in the development of custom applications utilizing Lectenz® reagents and GlycoSenseTM kits are being actively pursued. These partnerships will be with the biopharma industry that requires quality control metrics for glycosylated recombinant proteins for bioprocess monitoring and other applications.